Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMOTE-FL
NCT06948786Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- Nov 2025
- Primary completion
- Jul 2031
- Modality
- Monoclonal Antibodies, Bispecific Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirtobrutinib, mosunetuzumab in follicular lymphoma (FL), sponsored by University of Washington. Started Nov 2025; status: recruiting.
02
Drugs
pirtobrutinibmosunetuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06948786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06948786.